EE449 Outcome Assessment of Sofosbuvir / Velpatasvir for the Treatment of Patients with Hepatitis C in Colombia

Development of pangenotypic drugs with high clinical efficacy for the treatment hepatitis C virus (HCV) has changed disease’ management. This encouraged governments to make centralized purchases these drugs. The impact is not known, and our aim evaluate economic outcomes purchase sofosbuvir/velpatastir Colombian health system. Direct medical costs adjusted disease states, complications, adverse events, were calculated. A bottom-up approach which included medications, outpatient follow-up, diagnostic images, laboratory tests was used estimate direct costs. Prices taken from national tariff manuals medicines activities procedures. Indirect due work disabilities or premature retirement In Colombia there are approximately 554,000 patients HCV. Centralized sofosbuvir/velpatasvir at PAHO prices resulted in savings $ 20,816 per patient. weighted average healthcare cost a patient HCV 3,106, fifth year 6,946, tenth 12,363, twentieth 21,482. increase over time mainly driven by derived liver transplantation, loss productivity. However, generates saving Treatment Colombia's benefit reduction transplants